Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00464815
Other study ID # 109069
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date May 2, 2007
Est. completion date September 10, 2008

Study information

Verified date March 2018
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate, in 11-17 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.


Description:

Multicentre study with 2 treatment groups. Each subject will have 2 blood samples taken for immunogenicity analyses, one prior to vaccination and one taken 30 days later.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Recruitment information / eligibility

Status Completed
Enrollment 1025
Est. completion date September 10, 2008
Est. primary completion date April 16, 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 11 Years to 17 Years
Eligibility Inclusion Criteria:

- Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol.

- A male or female between, and including, 11 and 17 years of age at the time of the vaccination.

- Written informed assent/consent obtained from the subject/ from the parent or guardian of the subject.

- Healthy subjects as established by medical history and clinical examination before entering into the study.

- Previously completed routine childhood vaccinations to the best of the subject's/the subject's parent's/guardian's knowledge.

- If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after vaccination.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.

- Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine.

- Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W-135 and/or Y within the last five years.

- Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C, W-135 and/or Y.

- Previous vaccination with tetanus toxoid within the last month.

- History of meningococcal disease.

- Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.

- A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.

- History of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s).

- Major congenital defects or serious chronic illness.

- Acute disease at the time of enrolment.

- Administration of immunoglobulins and/or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.

- Pregnant or lactating female.

- History of chronic alcohol consumption and/or drug abuse.

- Female planning to become pregnant or planning to discontinue contraceptive precautions.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Meningococcal vaccine GSK134612
One intramuscular dose
Mencevax™ ACWY
One subcutaneous dose

Locations

Country Name City State
India GSK Investigational Site Goa
India GSK Investigational Site Indore
India GSK Investigational Site New Delhi
India GSK Investigational Site Pune
Philippines GSK Investigational Site Muntinlupa
Taiwan GSK Investigational Site Taipei
Taiwan GSK Investigational Site Tao Yuan County

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

India,  Philippines,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects With Vaccine Response to Meningococcal Antigens Vaccine response induced by Neisseria meningitidis serogroups A, C, W-135 and Y (MenA, MenC, MenW-135 and menY) as measured by serum bactericidal antibodies using baby rabbit complement (rSBA), was defined as an rSBA titer of at least 1:32 in subjects initially seronegative [rSBA titer below (<) 1:8] and as a 4-fold increase in titer in subjects initially seropositive [rSBA titer greater than or equal to (=) 1:8]. One month post-vaccination (At Month 1)
Primary Number of Subjects With Any Grade 3 General (Solicited and Unsolicited) Symptoms General symptoms assessed included fatigue, fever (defined as axillary temperature), gastrointestinal symptoms and headache. Grade 3 symptom= event that prevented normal activities. Grade 3 fever= temperature above (>) 39.5 degrees Celsius (°C). During the 4-day (Days 0-3) period after vaccination
Secondary Number of Subjects With rSBA-Men Antibody Titers = the Cut-off Values Neisseria meningitidis serogroups A, C, W-135 and Y were measured by serum bactericidal assay using baby rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY). The cut-off values for the rSBA titers was greater than or equal to (=) 1:8 and = 1:128. Prior to (Month 0) and one month after vaccination (Month 1)
Secondary Meningococcal rSBA Antibody Titers rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY antibody titers are presented as geometric mean titers (GMTs). Prior to (Month 0) and one month after vaccination (Month 1)
Secondary Number of Subjects With Anti-tetanus Toxoid (Anti-TT) Greater Than (>) the Cut-off Value The cut-off value of the assay was an anti-tetanus toxoid antibody titer greater than (>) 0.1 international units per milliliter (IU/mL). Prior to (Month 0) and one month after vaccination (Month 1)
Secondary Anti-TT Antibody Concentrations Antibody concentrations are presented as geometric mean concentrations (GMCs) and expressed in international units per milliliter (IU/mL). Prior to (Month 0) and one month after vaccination (Month 1)
Secondary Number of Subjects With Anti-meningococcal Polysaccharides (PS) Antibody Concentrations = the Cut-off Values The cut-off values of the assay was an anti-PS concentration greater than or equal to (=) 0.3 micrograms per milliliter (µg/mL) and = 2.0 µg/mL. Prior to (Month 0) and one month after vaccination (Month 1)
Secondary Anti-meningococcal Polysaccharide Concentrations Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in micrograms per milliliter (µg/mL). Prior to (Month 0) and one month after vaccination (Month 1)
Secondary Number of Subjects With Any and Grade 3 Solicited Local Symptoms Solicited local symptoms assessed included pain, redness and swelling. Any= incidence of a particular symptom regardless of intensity. Grade 3 symptoms= symptoms that prevented normal activity. Grade 3 swelling= swelling spreading beyond 50 millimeters (mm). During the 4-day (Days 0-3) period after vaccination
Secondary Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms Solicited general symptoms assessed included fatigue, fever [defined as axillary temperature equal to or above (=) 37.5 degrees Celsius (°C)]. Any= incidence of a particular symptom regardless of intensity or relationship to vaccination. Grade 3= event that prevented normal activities. Grade 3 fever= fever > 39.5 °C. Related= general symptom assessed by the investigator as causally related to the study vaccination. During the 4-day (Days 0-3) period after vaccination
Secondary Number of Subjects With Any Unsolicited Adverse Events An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. During the 31-day (Days 0-30) post-vaccination period
Secondary Number of Subjects With Any Serious Adverse Events (SAEs) Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. Up to study end (Month 6)
Secondary Number of Subjects With Specific Adverse Events These events consist of specific categories of adverse events (AEs) which included rash (e.g. hives, idiopathic thrombocytopenia purpura, petechiae), new onset of chronic illness(es) (NOCIs) (e.g. autoimmune disorders, asthma, type I diabetes and allergies), conditions prompting emergency room (ER) visits or non-routine physician office visits (i.e. office visits not related to well-being care, vaccination, injury or common acute illnesses such as upper respiratory tract infections, otitis media, pharyngitis, gastroenteritis), any events related to lack of meningococcal vaccine efficacy (i.e. meningococcal disease). Up to study end (Month 6)
See also
  Status Clinical Trial Phase
Completed NCT03652610 - A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age Phase 2
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Completed NCT00974363 - Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 Phase 3
Completed NCT00196950 - Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years Phase 2
Completed NCT00514904 - Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects Phase 3
Completed NCT02173704 - Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. Phase 3
Completed NCT01641042 - Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects Phase 3
Completed NCT01682876 - Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. Phase 3
Completed NCT00758264 - Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration Phase 3
Completed NCT01962207 - The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination Phase 3
Completed NCT00718666 - The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers Phase 2
Completed NCT01939158 - Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine Phase 3
Completed NCT01235975 - Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years Phase 3
Active, not recruiting NCT05082285 - A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants Phase 2
Completed NCT02446743 - Combined Study - Phase 3b MenB Long Term Persistence in Adolescents Phase 3
Completed NCT02946385 - Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents Phase 2
Completed NCT00674583 - Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children Phase 3
Completed NCT01777308 - Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination Phase 3
Completed NCT00661557 - Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects Phase 2
Completed NCT00196976 - Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old Phase 2